News

UCB retains exclusive rights to re-purchase each of the five programs, following completion of initial clinical feasibility studies for each program, and assume the responsibility for further development

The company has also filed several patents associated with the development of peptides and proteins derived from ‘state-dependent’ physiologies to advance the treatment of a variety of human

The safety and efficacy of AllerNaze nasal spray in both seasonal allergic rhinitis and perennial allergic rhinitis have been well established in 14 controlled clinical trials involving almost

Delayed graft function (DGF) represents Quark’s second indication being evaluated for the systemically administered drug candidate in human clinical trials. This trial follows two currently enrolling Phase I

Under the terms of the agreement EuroCept will pay Stellar an upfront milestone payment, plus an ongoing royalty on in-market sales and specified transfer price in exchange for

The Phase II trial is a double-blinded, randomized, dose-ranging, placebo-controlled study designed to assess cobiprostone’s efficacy and safety for preventing non-steroidal anti-inflammatory drugs-induced ulcers in patients with arthritis.

This commitment is part of Tekmira’s manufacturing relationship with Alnylam through Phase II clinical development for RNAi therapeutics that utilize Tekmira’s stable nucleic acid-lipid particles (SNALP) technology, including

Three separate sources of growth are expected to drive Monogram’s 2009 revenues: Increased sales of Trofile due to its clinically proven high level of sensitivity for selecting appropriate

Following a controlled allergen challenge in patients with mild asthma, TPI ASM8 did not demonstrate statistical significance in the primary efficacy endpoint – late asthmatic response. However, trends